Skin Surgery Techniques: Introduction

Publication of the phase 3 ARRECTOR trial findings precede an anticipated PDUFA date of May 22, 2025, for the investigational foam, now under FDA review.

PODCAST: Listen to our first episode for new research on bacterial vaginosis, a new treatment option for chronic urticaria, and more.

New data also demonstrated mixed sex disparities in elderly atopic dermatitis prevalence.

At one time or another, every primary care physician will likely see a patient who is a hypochondriac, a chronic complainer, or a substance abuser. Rather than seeing these patients as difficult and avoiding them as much as possible, the physician can reframe the problem as an opportunity for growth and development. Dr Lieberman suggests that keeping the sessions brief but allowing more frequent visits and addressing medical and psychosocial concerns will make your relationship with your patient more positive. Managing hypochondriacal patients, chronic complainers, and substance abusers will be much easier after listening to Dr Lieberman’s suggestions.

New data highlight the potential of dupilumab, remibrutinib, and barzolvolimab to expand treatment options for patients with CSU unresponsive to current therapies.

Your daily dose of the clinical news you may have missed.